La Jolla Pharmaceutical Company Stock News

The stock price of La Jolla Pharmaceutical Company (NASDAQ: LJPC) surged by over 80% during intraday trading today. This is why.

La Jolla Pharmaceutical press release (LJPC): Q4 GAAP EPS of $0.11 beats by $0.07.Revenue of $12.2M (+10.9% Y/Y) misses by $1.83M.Shares +5.47%.

Zacks Investment Research upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. They currently have $5.00 price objective on the biopharmaceutical companys stock. According to Zacks, LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development []

La Jolla Pharmaceutical (NASDAQ:LJPC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. “ NASDAQ:LJPC opened […]

La Jolla Pharmaceutical Company (NASDAQ:LJPC) price on Friday, December 10, rose 5.08% above its previous days close as an upside momentum from buyers pushed the stocks value to $4.55. A look at the stocks price movement, the close in the last trading session was $4.33. The beta value (5-Year monthly) was 2.36 while the PE La Jolla Pharmaceutical Company (NASDAQ: LJPC) Rise 5.08%, Now What? Dont Panic Read More »

Zacks Investment Research upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a hold rating to a buy rating in a report released on Saturday, Zacks.com reports. The brokerage currently has $4.25 price target on the biopharmaceutical companys stock. According to Zacks, LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products [] The post La Jolla Pharmaceutical (NASDAQ:LJPC) Rating Increased to Buy at Zacks Investment Research appeared first on ETF Daily News .

Millennium Management LLC raised its holdings in shares of La Jolla Pharmaceutical (NASDAQ:LJPC) by 128.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 401,819 shares of the biopharmaceutical companys stock after purchasing an additional 225,983 shares during the quarter. Millennium Management LLCs []

La Jolla Pharmaceutical (NASDAQ:LJPC) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to investors on Saturday, Zacks.com reports. The brokerage currently has a $4.25 target price on the biopharmaceutical companys stock. Zacks Investment Researchs target price indicates a potential upside of 13.03% from the []

Geode Capital Management LLC lessened its holdings in La Jolla Pharmaceutical (NASDAQ:LJPC) by 34.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 274,361 shares of the biopharmaceutical companys stock after selling 142,226 shares during the quarter. Geode Capital Management LLC owned []

La Jolla Pharmaceutical (NASDAQ:LJPC) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The brokerage presently has a $5.00 price objective on the biopharmaceutical companys stock. Zacks Investment Researchs target price would indicate a potential upside of 8.70% from the []

La Jolla Pharmaceutical (NASDAQ:LJPC) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Saturday, Zacks.com reports. According to Zacks, LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory []

La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock

WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients s

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto